JP2002505841A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002505841A5 JP2002505841A5 JP2000509728A JP2000509728A JP2002505841A5 JP 2002505841 A5 JP2002505841 A5 JP 2002505841A5 JP 2000509728 A JP2000509728 A JP 2000509728A JP 2000509728 A JP2000509728 A JP 2000509728A JP 2002505841 A5 JP2002505841 A5 JP 2002505841A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- polypeptide
- nucleic acid
- molecule
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 description 17
- 102000004196 processed proteins & peptides Human genes 0.000 description 17
- 108090000765 processed proteins & peptides Proteins 0.000 description 17
- 108020004707 nucleic acids Proteins 0.000 description 12
- 102000039446 nucleic acids Human genes 0.000 description 12
- 150000007523 nucleic acids Chemical class 0.000 description 12
- 125000003275 alpha amino acid group Chemical group 0.000 description 10
- 239000002773 nucleotide Substances 0.000 description 10
- 125000003729 nucleotide group Chemical group 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 5
- 239000003814 drug Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5645397P | 1997-08-21 | 1997-08-21 | |
| US60/056,453 | 1997-08-21 | ||
| PCT/US1998/017296 WO1999009049A1 (en) | 1997-08-21 | 1998-08-21 | Hypoxia-regulated genes |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009142675A Division JP2009261396A (ja) | 1997-08-21 | 2009-06-15 | 低酸素調節性遺伝子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002505841A JP2002505841A (ja) | 2002-02-26 |
| JP2002505841A5 true JP2002505841A5 (enExample) | 2006-02-16 |
| JP4354633B2 JP4354633B2 (ja) | 2009-10-28 |
Family
ID=22004501
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000509728A Expired - Fee Related JP4354633B2 (ja) | 1997-08-21 | 1998-08-21 | 低酸素調節性遺伝子 |
| JP2009142675A Pending JP2009261396A (ja) | 1997-08-21 | 2009-06-15 | 低酸素調節性遺伝子 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009142675A Pending JP2009261396A (ja) | 1997-08-21 | 2009-06-15 | 低酸素調節性遺伝子 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US6455674B1 (enExample) |
| EP (2) | EP1015471A1 (enExample) |
| JP (2) | JP4354633B2 (enExample) |
| AT (1) | ATE293633T1 (enExample) |
| AU (2) | AU9110798A (enExample) |
| DE (1) | DE69829857T2 (enExample) |
| IL (2) | IL134298A0 (enExample) |
| WO (2) | WO1999009046A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7973156B2 (en) | 1997-08-21 | 2011-07-05 | Quark Pharmaceuticals Inc. | Hypoxia-regulated genes |
| WO2001023426A2 (en) * | 1999-09-30 | 2001-04-05 | Varian Associates, Inc. | Hypoxia-related human genes, proteins, and uses thereof |
| AU2001268466A1 (en) * | 2000-06-13 | 2001-12-24 | Agensys, Inc. | 55p4h4: gene expressed in various cancers |
| AU2001290179B2 (en) * | 2000-08-07 | 2007-07-12 | Angiogenetics Sweden Ab | Mechanism of conditional regulation of the hypoxia-inducible factor-1 by the von hippel-lindau tumor suppressor protein |
| US7105656B2 (en) | 2000-10-26 | 2006-09-12 | The Brigham And Women's Hospital, Inc. | Compositions and methods for treating hematologic malignancies and multiple drug resistance |
| WO2003070906A2 (en) * | 2002-02-19 | 2003-08-28 | The Children's Hospital Of Philadelphia | Cellular genes regulated by hiv-1 infection and methods of use thereof |
| US7405292B2 (en) | 2002-02-19 | 2008-07-29 | The Children's Hospital Of Philadelphia | Cellular genes regulated by HIV-1 infection and methods of use thereof |
| KR100939274B1 (ko) * | 2004-08-16 | 2010-01-29 | 쿠아크 파마수티칼스 인코퍼레이티드 | 알티피801 억제제의 치료적 용도 |
| DK1791568T3 (da) * | 2004-08-16 | 2012-12-10 | Quark Pharmaceuticals Inc | Terapeutiske anvendelser af hæmmere af rtp801 |
| NL2000439C2 (nl) * | 2006-01-20 | 2009-03-16 | Quark Biotech | Therapeutische toepassingen van inhibitoren van RTP801. |
| US7825099B2 (en) | 2006-01-20 | 2010-11-02 | Quark Pharmaceuticals, Inc. | Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes |
| WO2008054534A2 (en) * | 2006-05-11 | 2008-05-08 | Quark Pharmaceuticals, Inc. | Screening systems utilizing rtp801 |
| EP2026843A4 (en) | 2006-06-09 | 2011-06-22 | Quark Pharmaceuticals Inc | THERAPEUTIC USES OF RTP801L INHIBITORS |
| JP2010507387A (ja) | 2006-10-25 | 2010-03-11 | クアーク・ファーマスーティカルス、インコーポレイテッド | 新規のｓｉＲＮＡおよびその使用方法 |
| EP2137205A2 (en) | 2007-02-26 | 2009-12-30 | Quark Pharmaceuticals, Inc. | Inhibitors of rtp801 and their use in disease treatment |
| CA2701845A1 (en) | 2007-10-03 | 2009-04-09 | Quark Pharmaceuticals, Inc. | Novel sirna structures |
| US8614311B2 (en) | 2007-12-12 | 2013-12-24 | Quark Pharmaceuticals, Inc. | RTP801L siRNA compounds and methods of use thereof |
| US20110105584A1 (en) * | 2007-12-12 | 2011-05-05 | Elena Feinstein | Rtp80il sirna compounds and methods of use thereof |
| US20140323549A1 (en) | 2011-11-08 | 2014-10-30 | Quark Pharmaceuticals, Inc. | Methods and compositions for treating diseases, disorders or injury of the nervous system |
| CA2880290C (en) | 2012-09-12 | 2020-10-27 | Quark Pharmaceuticals, Inc. | Double-stranded oligonucleotide molecules targeting p53 and methods of use thereof |
| JP2014069592A (ja) * | 2012-09-27 | 2014-04-21 | Mitsubishi Motors Corp | 車載機器の遠隔操作システム |
| US12023781B2 (en) | 2018-03-26 | 2024-07-02 | Sintokogio, Ltd. | Shot processing apparatus |
| CN114940975B (zh) * | 2022-06-20 | 2023-07-25 | 中国人民解放军总医院 | 一种ted缺失的细胞系及其应用 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1182829A (en) | 1967-06-12 | 1970-03-04 | Haldor Frederik Axel Topsoe | Improvements in or relating to Nickel Catalysts. |
| NL154600B (nl) * | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
| US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
| NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
| US3838153A (en) | 1972-05-16 | 1974-09-24 | Pfizer | 6-(alpha-(guanylureidoalkanoylamino)aracylamino)penicillanic acids |
| US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
| US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
| US3850572A (en) | 1974-03-08 | 1974-11-26 | E Andrus | Gravity flow discrete article gas flow isolated thermal treatment device and method |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
| US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
| US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
| US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
| US4736866B1 (en) | 1984-06-22 | 1988-04-12 | Transgenic non-human mammals | |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| ATE132266T1 (de) | 1987-05-01 | 1996-01-15 | Stratagene Inc | Mutagenesetest durch verwendung von nicht menschlichen lebewesen, die test-dns-sequenzen enthalten |
| US5175385A (en) | 1987-09-03 | 1992-12-29 | Ohio University/Edison Animal Biotechnolgy Center | Virus-resistant transgenic mice |
| US4866042A (en) | 1987-11-18 | 1989-09-12 | Neuwelt Edward A | Method for the delivery of genetic material across the blood brain barrier |
| US5221778A (en) | 1988-08-24 | 1993-06-22 | Yale University | Multiplex gene regulation |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5175383A (en) | 1989-02-17 | 1992-12-29 | President And Fellows Of Harvard College | Animal model for benign prostatic disease |
| US5464764A (en) | 1989-08-22 | 1995-11-07 | University Of Utah Research Foundation | Positive-negative selection methods and vectors |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5225347A (en) | 1989-09-25 | 1993-07-06 | Innovir Laboratories, Inc. | Therapeutic ribozyme compositions and expression vectors |
| US5614396A (en) | 1990-06-14 | 1997-03-25 | Baylor College Of Medicine | Methods for the genetic modification of endogenous genes in animal cells by homologous recombination |
| US5387742A (en) | 1990-06-15 | 1995-02-07 | Scios Nova Inc. | Transgenic mice displaying the amyloid-forming pathology of alzheimer's disease |
| US5288846A (en) | 1990-10-19 | 1994-02-22 | The General Hospital Corporation | Cell specific gene regulators |
| NO176546C (no) | 1991-07-09 | 1995-04-26 | Soda Galvano As | Anordning for sammenföyning av delkomponenter i möbler |
| US5298422A (en) | 1991-11-06 | 1994-03-29 | Baylor College Of Medicine | Myogenic vector systems |
| US5360735A (en) | 1992-01-08 | 1994-11-01 | Synaptic Pharmaceutical Corporation | DNA encoding a human 5-HT1F receptor, vectors, and host cells |
| US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
| EP0663952A4 (en) | 1992-09-11 | 1997-06-11 | Univ California | Transgenic non-human animals having targeted lymphocyte transduction genes. |
| WO1994023049A2 (en) | 1993-04-02 | 1994-10-13 | The Johns Hopkins University | The introduction and expression of large genomic sequences in transgenic animals |
| US6664107B1 (en) | 1993-05-26 | 2003-12-16 | Ontario Cancer Institute, University Health Network | CD45 disrupted nucleic acid |
| US5721265A (en) * | 1994-08-05 | 1998-02-24 | Sri International | Fluorinated 2-nitroimidazole analogs for detecting hypoxic tumor cells |
| US5882914A (en) * | 1995-06-06 | 1999-03-16 | The Johns Hopkins University School Of Medicine | Nucleic acids encoding the hypoxia inducible factor-1 |
-
1998
- 1998-08-21 WO PCT/US1998/017297 patent/WO1999009046A1/en not_active Ceased
- 1998-08-21 EP EP98942168A patent/EP1015471A1/en not_active Withdrawn
- 1998-08-21 AU AU91107/98A patent/AU9110798A/en not_active Abandoned
- 1998-08-21 AT AT98943278T patent/ATE293633T1/de active
- 1998-08-21 AU AU90282/98A patent/AU9028298A/en not_active Abandoned
- 1998-08-21 WO PCT/US1998/017296 patent/WO1999009049A1/en not_active Ceased
- 1998-08-21 JP JP2000509728A patent/JP4354633B2/ja not_active Expired - Fee Related
- 1998-08-21 IL IL13429898A patent/IL134298A0/xx not_active IP Right Cessation
- 1998-08-21 DE DE69829857T patent/DE69829857T2/de not_active Expired - Lifetime
- 1998-08-21 EP EP98943278A patent/EP1009753B1/en not_active Expired - Lifetime
-
2000
- 2000-06-28 US US09/604,978 patent/US6455674B1/en not_active Expired - Lifetime
- 2000-06-28 US US09/604,728 patent/US6555667B1/en not_active Expired - Lifetime
-
2002
- 2002-12-23 US US10/325,878 patent/US6740738B2/en not_active Expired - Lifetime
-
2008
- 2008-01-15 IL IL188791A patent/IL188791A0/en unknown
-
2009
- 2009-06-15 JP JP2009142675A patent/JP2009261396A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002505841A5 (enExample) | ||
| Carr et al. | A helix-loop-helix protein related to the immunoglobulin E box-binding proteins | |
| JP2003515323A5 (enExample) | ||
| NZ503763A (en) | Antigenic compositions and vaccines comprising a high molecular weight (HMW) protein of Clamydia for therapeutic and prophylactic use | |
| KR960022562A (ko) | 항-αV-인터그린 모노크로날 항체 | |
| WO2006038027A3 (en) | SINGLE DOMAIN ANTIBODIES AGAINST TNFRl AND METHODS OF USE THEREFOR | |
| DE60236965D1 (de) | Coronavirus-ähnliche partikel enthaltende funktionell deletierte genome | |
| JP2002503495A5 (enExample) | ||
| DK1265914T3 (da) | WNT-1-relaterede polypeptider og nukleinsyrer, der koder for samme | |
| ATE269902T1 (de) | Cytokinähnliches polypeptid-10 aus säugetieren | |
| EP2343318A3 (en) | Antibodies binding to a C-terminal fragment of apolipoprotein E | |
| NZ595896A (en) | Genetic products differentially expressed in tumors and the use thereof | |
| Hwang et al. | Improvement of RNA aptamer activity against myasthenic autoantibodies by extended sequence selection | |
| NZ607886A (en) | Nogo receptor binding protein | |
| NZ596981A (en) | Compositions and methods for the treatment of tumor of hematopoietic origin | |
| JP2002525081A5 (enExample) | ||
| CA2319715A1 (en) | Breast cancer resistance protein (bcrp) and the dna which encodes it | |
| WO2003022298A3 (fr) | Utilisation d'une proteine de la famille des crmps pour le traitement des maladies liees au systeme immunitaire | |
| WO2004067564B1 (en) | Compositions against cancer antigen liv-1 and uses thereof | |
| JP2006524491A5 (enExample) | ||
| Wolkowicz et al. | Augmented DNA-binding activity of p53 protein encoded by a carboxyl-terminal alternatively spliced mRNA is blocked by p53 protein encoded by the regularly spliced form. | |
| WO2001036626A3 (en) | Pentraxin i and pentraxin receptor, inhibitors of said proteins and pharmaceutical compositions containing said compounds | |
| JP2007534772A5 (enExample) | ||
| WO2005058362A3 (en) | Method for opening tight junctions comprising the use of jam-1, claudin-4 and occludin protein antagonists as well as sirna molecules | |
| JP2008509659A5 (enExample) |